Objectives: To determine if integrating VDOT into TB therapy demonstrated non-inferiority to direct observation, and if VDOT utilization increased across Florida after the onset of Covid-19.
Methods: A statewide programmatic review was conducted of all patients in Florida who initiated tuberculosis treatment between January 2018 - December 2018 and January 2020 - December 2021, as documented by the Florida Department of Health.
Results: 1361 patients received treatment within the analysis timeframe.
Background: Concern for drug-drug interactions leading to treatment failure and drug-resistant strains have discouraged clinicians from attempting concomitant treatment of hepatitis C virus (HCV) and tuberculosis (TB). Increased metabolism of direct-acting antivirals (DAAs) by rifamycins has hindered concurrent use. Development of an assay for ledipasvir and sofosbuvir (LDV/SOF) serum concentrations for therapeutic drug monitoring (TDM) can ensure adequate therapy.
View Article and Find Full Text PDFClin Infect Dis
October 2023